Description
The inventors discovered that proteins produced in insect cells by standard baculovirus expression systems are glycosylated in a unique way, which causes them to be selectively taken up by cells of the reticuloendothelial system, including macrophages. This discovery has particular significance for proteins used to treat lysosomal storage disorders(LSDs) in which the primary therapeutic target for such proteins are macrophages. Simply by producing such proteins in insect cells, this discovery reveals that they will be targeted for uptake by macrophages.
Keywords
Lysosomal storage disorder, macrophage, baculovirus, insect cell, protein production
Granted Patents or Published Applications
U.S. Patent Nos. 7,232,670 and 7,241,442
Related Scientific References
Bonten et al., American Journal of Human Genetics, Suppl. Vol. 69 (4): Abst.1759 (Oct. 2001);
Bonten EJ, et al., "Targeting macrophages with baculovirus-produced lysosomal enzymes: implications for enzyme replacement therapy of the glycoprotein storage disorder galactosialidosis", FASEB J. 18(9): 971-973 (June 2004).
Licensing Opportunities
We are currently seeking licensing opportunities in all fields for the development of this technology. Contact: chad.riggs@stjude.org
Related Links
- Activation of Prodrugs by Carboxylesterase (SJ-98-0001)
- Anti-GD2-BB-zeta Chimeric Receptor for Treating GD2+ Malignancies (SJ-13-0035)
- Antibodies to Tim4 for use as an Immune Enhancer and Cancer Therapeutic (SJ-18-0006)
- Association of Neuraminidase Regulated Exocytosis with Cancer Metastasis (SJ-11-0012)
- BCRP/ABCG2 as Stem Cell Marker (SJ-97-0016)
- CD33 CAR (SJ-17-0010)
- CD7 CAR placed in CD7neg memory cells (SJ-15-0020)
- Chimeric gene and protein that can be used to create Optogranules: Light induced stress granules (SJ-18-0010)
- Development and Optimization of a Serotype-Independent Method of Adeno-Associated Virus (AAV) Harvest and Purification (SJ-16-0036)
- DNA Methylation Profile and Biomarkers for identifying functional T-cells (SJ-17-0002)
- DNMT3a knockout CAR T cells with Antigen Specificity (for solid tumors) (SJ-19-0024)
- Efficient generation of T-Cell Receptor (TCR) sequences in response to a variety of immune responses (SJ-19-0017)
- Erythroid Specific Promoter for Hematopoietic Disorders (SJ-16-0040)
- Gene Therapy for Wiskott-Aldrich Syndrome (SJ-19-0012)
- Generation of Therapeutic T Cell Receptors for Fibrolamellar Cancer (SJ-19-0046)
- HMGA2 in Gene Therapy Vectors (SJ-16-0014)
- Hybrid Compounds to treat Gastrointestinal Infections (SJ-14-0019/UTA 14-01)
- IL35 Receptor (SJ-08-0039)
- Immune Cells with DNMT3A Gene Modifications (SJ-16-0009)
- Improved GD2 Ab for Neuroblastoma (SJ-17-0017)
- Interleukin-35 (IL-35) (SJ-06-0016)
- Method for Enhancing Recombinant Antibody Production (SJ-08-0032)
- Method for predicting T-cell development stage (and therapy success) (SJ-19-0033)
- Minimized Liver Specific Promoter for Improved Gene Expression in Gene Therapy Vectors (SJ-04-0024)
- miRNAs for Treating Cerebral Ventricle Enlargement in Schizophrenia Patients (SJ-19-0039)
- Myd88 and CD40 Costimulatory Domains for Chimeric Antigen Receptors (SJ-18-0021)
- New Method for Differentiating T-cells (SJ-18-0019)
- p53 Inhibitory Oligonucloeotides (SJ-09-0015)
- Protease Serine 21 (PRSS21) Targeted Immunotherapies (SJ-18-0043)
- Rapid Cloning of T Cell Receptors (SJ-16-0001)
- REGNASE-1 Gene Knockout or BATF Overexpression for Improving T-cell Function (SJ-19-0027, SJ-20-0007)
- Regulating p53 Translation and Function (SJ-05-0002)
- RIPK3 Fusion Protein for Treating Cancer and Autoimmunity (SJ-12-0036)
- Safety Test for Gene Therapy Vectors (SJ-15-0027)
Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.